The chase for the RIG-I ligand--recent advances

Area of Science:

• Immunology
• Virology
• Molecular Biology

Background:

• Multicellular organisms utilize host-defense mechanisms to combat viral infections.
• RNA interference (RNAi) is a primary antiviral strategy in invertebrates and plants.
• Mammalian antiviral defense relies on innate receptors like RIG-I-like helicases (RLHs) and Toll-like receptors (TLRs) to detect viral nucleic acids.

Purpose of the Study:

• To provide a comprehensive overview of the literature on ligand structures recognized by RIG-I.
• To define the molecular characteristics of the RIG-I ligand.
• To explore the therapeutic potential of RIG-I ligand-based strategies.

Main Methods:

• Literature review of current research on RIG-I and its ligands.
• Analysis of molecular structures recognized by RIG-I.
• Discussion of the implications for designing antiviral therapeutics.

Main Results:

• RLHs, including RIG-I, are crucial for sensing viral RNA and DNA in the cell cytoplasm.
• RIG-I activation initiates antiviral responses such as type I interferon production, inflammasome activation, and apoptosis.
• The molecular definition of the RIG-I ligand is established as short, blunt-ended, 5'-triphosphate double-stranded RNA.

Conclusions:

• The precise definition of the RIG-I ligand enables the rational design of short double-stranded RNA (dsRNA) oligonucleotides.
• These dsRNA oligonucleotides can be used alone or with small-interfering RNA (siRNA) for therapeutic interventions.
• This approach holds promise for treating viral infections and cancers.